Organisation paid for research Program year 2023 Source: CMS Open Payments

Centex Studies, Inc.

Neither a doctor nor a teaching hospital

Research payments

$677,196

41 payments

Through program year 2023, Centex Studies, Inc. is reported as receiving $677,196 in research payments, across 41 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $187 1
2022 Research $159 1
2021 Research $63,799 28
2020 Research $280 1
2019 Research $612,771 10

Breakdown

Who paid Research payments · program years 2019–2023
  1. Romark Laboratories, LC $600,643 3 payments
  2. Merck Sharp & Dohme Corporation $61,111 6 payments
  3. Kowa Research Institute, Inc. $8,627 6 payments
  4. Chiesi USA, Inc. $3,500 1 payment
  5. Organon LLC $2,422 11 payments
  6. Alnylam Pharmaceuticals Inc. $546 12 payments
  7. E.R. Squibb & Sons, L.L.C. $346 2 payments
Studies the money was for Research payments · program years 2019–2023
  1. Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection $507,211 2 payments
  2. A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza $93,432 1 payment
  3. A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK-8415 Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger $45,663 11 payments
  4. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V590 rVSV G-SARS-CoV-2-S, Live in Healthy Individuals 16 Years of Age or Older $15,000 1 payment
  5. K-877-301 $5,715 4 payments
  6. Ccd-05993Aa3-02 $3,500 1 payment
  7. K-877-303 $2,913 2 payments
  8. 8415-8415-060-PN060-Extended Duration Study (Celanese + 2 years)-Contraception-SC-imp-Supplemental Registration-USA-LD-B $2,089 2 payments
  9. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) $546 12 payments
  10. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V591 MV SARS-CoV-2, Live, Recombinant in Healthy Individuals 16 Years of Age or Older $500 1 payment
What the money was spent on Research payments · program years 2019–2023
  1. Patient care $2,422 11 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record